BetaGlue Technologies is pioneering a novel radiotherapy platform known as YntraDose®, designed for the targeted and personalized treatment of solid tumors. This innovative approach aims to address the limitations of existing radiotherapy methods, such as Stereotactic Body Radiotherapy (SBRT) and Proton Beam Radiotherapy (PBRT), which often struggle with issues like internal organ movement and require significant investment in specialized equipment. YntraDose® seeks to enhance treatment efficacy while minimizing side effects, making personalized cancer treatment more accessible to a broader range of patients.

The YntraDose® platform has shown promising preliminary safety and effectiveness in clinical settings, indicating its potential to become a new standard of care for various solid tumor patient groups. By offering an easy-to-use interventional oncology treatment option, BetaGlue Technologies is committed to improving patient outcomes and providing healthcare professionals with a versatile tool to better manage cancer treatment. As the technology continues to develop, it holds the promise of transforming the landscape of cancer therapy, particularly for those patients who currently have limited treatment options.

Italy

BetaGlue Therapeutics is a clinical stage oncology company that has developed  an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose.

BetaGlue Technologies

Company Details